Tharimmune Clarifies Director Independence Ahead of Special Meeting

summarizeSummary

Tharimmune, Inc. filed a supplement to its proxy statement, clarifying that its two director nominees, William Wiley and Jill E. Sommers, are independent according to Nasdaq rules, addressing a prior non-compliance notice.

check_boxKey Events

• Director Independence Confirmed

  The company clarified that proposed director nominees, William Wiley and Jill E. Sommers, meet Nasdaq's independence requirements.

• Addresses Prior Nasdaq Non-Compliance

  This clarification directly relates to the Nasdaq non-compliance notice received on January 15, 2026, regarding board independence.

• Supplement to Special Meeting Proxy

  The filing supplements the definitive proxy statement for the January 30, 2026 Special Meeting, where these directors are up for election.

auto_awesomeAnalysis

This DEFA14A filing provides crucial clarification regarding the independence status of two director nominees, William Wiley and Jill E. Sommers. This directly addresses the Nasdaq non-compliance notice received on January 15, 2026, which cited a failure to meet board independence requirements. By confirming the independence of these nominees, Tharimmune is taking a positive step towards resolving its governance issues ahead of the January 30, 2026 Special Meeting, where their election will be voted upon. While this supplement does not alter the dilutive proposals previously disclosed on January 16, 2026, it signals progress in meeting regulatory standards.